1.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CT 07-03, NCT00516685
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EMR 63325-001, NCT00409188
|
|
3.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: NR001-03, BB-IND 8868, NCT00676507
|
|
4.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: NCI-04-C-0049, NLGC-0101, NCT00075790
|
|
5.
|
Phase: Phase II, Phase I
Type: Diagnostic, Treatment
Status: Active
Age: No age specified
Sponsor: Other
Protocol IDs: A/100/0601, NCT00298298
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 20 to 85
Sponsor: Other
Protocol IDs: IMS-NSCLC02, NCT00673777
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 20 to 85
Sponsor: Other
Protocol IDs: IMS-NSCLC24, NCT00674258
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0359-08-HMO-CTIL, NCT00722228
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 to 80
Sponsor: Other
Protocol IDs: sor469208ctil, NCT00828022
|
|
10.
|
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: Over 18
Sponsor: Other
Protocol IDs: 191203-HMO-CTIL, NCT00162500
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: Dendric cells in lungcancer, NCT00442754
|
|
12.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: MCC-15206, MCC-IRB-9792, MCC 15206, INTROGEN-RAC-0705-857, NCT00618891
|
|
13.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MCC-14744, MCC 14744, MCC-104490, MCC-0534-NE, NIH-OBA-0608-801, NCT00601796
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-14955, USFIRB#105632, NCT00609583
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CTN-0505, UKIRB 06-0716-F3R, ULIRB 065.07, CIRB 1079747, NCT00654030
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E6508, E6508, NCT00828009
|
|
17.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CCL5001-01, NCT00062907
|
|
18.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: R04-10-009, NCT00265603
|
|
19.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 21
Sponsor: NCI
Protocol IDs: UCLA-NCI-7888, 7888, NCT00601094
|
|
20.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: JX594-IV-011, NCT00625456
|
|
21.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GI-4000-03, NCT00655161
|
|
22.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 20-80 years old
Sponsor: Other
Protocol IDs: KU-CY5peptides, No, NCT00676949
|
|
23.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2008_541, V934-002, NCT00753415
|
|
24.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NYU 05-409, NCT00821652
|
|
25.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: UPCI 08-004, #PRO08030405, BB-IND 13252, NCT00793208
|
